| Gross sales for the quarter stood at Rs 163.15 crore as compared to Rs 127.02 crore in the corresponding period of last year, an increase of 28.43 per cent. Exports contributed 56 per cent to the gross sales during the quarter. |
| The company has filed four drug master files (DMFs) with the US Food and Drug Administration (US FDA) during the first quarter. |
| With the latest, the total number of DMFs filed with US FDA so far has gone up to 24. This includes five DMFs filed by Vera Laboratories, the company that is being merged with Matrix. |
| Recently, Vera Laboratories received US FDA approval for its DMF for the anti-depressant drug Trazodone. |
| "We are on track to file at least 18 US DMFs during the current financial year, as targeted earlier," N Prasad, chairman and CEO of Matrix Laboratories, said in a press release. |
| The company filed a total number of 12 process patents during the first quarter of this fiscal. The board of directors at its meeting held here on July 17 took an in-principle decision to introduce employee stock option scheme (ESOS). |
| The paid-up share capital of the company has increased by Rs 2.25 crore to Rs 14.55 crore following the issue of 22, 50,000 equity shares of Rs 10 each at a price of Rs 1,500 per share on preferential basis to India Newbridge Investments Limited (an investment vehicle of Newbridge capital, US) and Maxwell (Mauritius) Pte Ltd (an investment vehicle of the Singapore Government owned Temasek Holdings). |
| With the share premium that was paid by the two strategic investors, the networth of the company increased to Rs 607.5 crore as on June 30, 2004, reflecting a book value of Rs 417 per share. |
| The new unit set up at Kazipally, near Hyderabad, with an investment of about Rs 40 crore and was commissioned at the end of last financial year has since commenced commercial operations. |
| The matter has been referred to the remuneration committee of the board for working out the details. |
Top Section
Explore Business Standard